Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium tetrad live bacteria tablet placebo + helicobacter pylori quadruple eradication therapy
- Development stage
- Unknown
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug regimen is the placebo-controlled comparator arm used in clinical trials (notably NCT04034641) evaluating the probiotic Si Lian Kang (Bifidobacterium tetrad live bacteria tablets). It consists of a standard bismuth-containing quadruple eradication therapy—comprising esomeprazole, amoxicillin, furazolidone, and bismuth potassium citrate—administered alongside a starch-based placebo. The regimen is designed to treat *Helicobacter pylori* infection by combining acid suppression, multiple antibiotic mechanisms, and the bactericidal properties of bismuth. The trial context focuses on whether adding live probiotics to this standard regimen can reduce common gastrointestinal side effects and improve overall eradication rates.
- Brand names
- Si Lian Kang
- Other names
- bismuth-containing quadruple therapyH. pylori quadruple eradication therapyesomeprazole + amoxicillin + furazolidone + bismuth potassium citrate
02
Targets
PBP (Penicillin-binding protein family)DNAATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on bifidobacterium tetrad live bacteria tablet placebo + helicobacter pylori quadruple eradication therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium tetrad live bacteria tablet placebo + helicobacter pylori quadruple eradication therapy.